Skip to content
DataLookout
Menu

SparkleNCT07287982

A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy

StatusRecruiting
PhasePhase 2
Sponsorargenx
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 14 versions: 14 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 28 → 46 locations
  2. Notable Eligibility criteria expanded, about 10 words
    • Trial sites expanded: 23 → 28 locations
    • Secondary endpoints: details revised at 1 of 3 entries
  3. Minor Site details revised at 1 of 23 sitesv12
  4. Minor Study sites: 24 to 23v11
  5. Minor Site details revised at 1 of 24 sitesv10
  6. Minor Trial sites expanded: 17 → 24 locationsv9
  7. Minor Site details revised at 1 of 17 sitesv8
  8. Minor Site details revised at 1 of 17 sitesv7
  9. Minor Site details revised at 1 of 17 sitesv6
  10. Minor Site contacts updated at 1 of 17 sitesv5
  11. Minor Study sites: 15 to 17v4
  12. Minor Study sites: 2 to 15v3
  13. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 2
    v2
  14. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Incidence of AEs
Timeframe: Up to 124 weeks
Incidence of SAEs
Timeframe: Up to 124 weeks
Change in RHS total score from baseline to week 24 of the double blinded treatment period (DBTP)
Timeframe: Up to 24 weeks

Secondary (3)

Change from baseline over time for the 6MWT - distance and fatigue index
ARGX-119 serum concentrations over time
Incidence of antidrug antibodies (ADA) against ARGX-119

Arms and interventions

DBTP - ARGX-119 IVExperimental

Participants receive ARGX-119 IV during the DBTP

DBTP - Placebo IVPlacebo comparator

Participants receive placebo IV during the DBTP

ATEP - ARGX-119 IVPlacebo comparator

Participants receive ARGX-119 IV during the ATEP. Participants from ARGX-119 IV arm in the DBTP will receive placebo once to maintain the DBTP blinding

Biologicals: ARGX-119 IV

Other: Placebo IV

Sites

46 sites in 10 countries

United States 16, United Kingdom 7, Italy 5, Germany 4, Belgium 3, Canada 3, Poland 3, Australia 2, Spain 2, Netherlands 1